Fig. 4
SS-USCs inhibit ferroptosis to alleviate SHP-HR through the utilization of Exosomes. A Flow cytometry analysis of cell death rates; the exosome inhibitor GW4869 significantly attenuates the protective effect of SS-USCs on cell damage (n = 3). B Elevated levels of Lipid ROS after treatment of SS-USCs with GW4869. C Transmission electron microscopy image showing exosomes isolated from USCs conditioned medium (scale bar = 200 nm).D Analysis of size distribution of USCs-Exo, revealing an average diameter of 102.4 ± 9.8 nm. E Western blot validation of exosome markers CD9, CD63, CD81, and HSP70, with conditioned medium (CM) as the control group. F Cell viability measured by CCK-8 assay (n = 3). G Fluorescence images showing S-HL7702 cells uptake CM-DiI-labeled (red) exosomes. H Flow cytometry analysis of cell death rates across different treatment groups (HR, RS-USCs-Exo, SS-USCs-Exo) (n = 3). I CCK-8 assay measuring cell viability (n = 3). J Elevated Fe2⁺ levels after treating SS-USCs with GW4869. K Lipid ROS levels (C11-BODIPY) detection in various treatment groups (HR, RS-USCs-Exo, SS-USCs-Exo) (n = 3). L, M Measurement of MDA and Fe2 + levels in cells from each group (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001